Latest news with #LSR
Indian Express
30-05-2025
- General
- Indian Express
Delhi University's LSR offers course in Parsi culture in Summer School 2025
Lady Shri Ram (LSR) College has announced its Summer School 2025 under the theme 'Tapestries of Indian Culture' with one of it's certification courses offering insights into the Parsi Zoroastrian culture in India. This year's summer school, offered by the premier institution's Internal Quality Assurance Cell, will offer three online certification courses in its summer school. One of the courses, namely 'An Introduction to Zoroastrianism – Continuity and Change', is aimed at building an understanding Parsi culture and heritage, and the evolution of the Zoroastrian belief system. It will also put an emphasis on the migration of the Parsi community, the integration and diversity of its diaspora, and their contributions to modern India. The course will delve into the Parsi artistic expressions and explore embroidery and devotional music. It will also help students analyse the role and representation of women in Parsi culture. Comprising 12 online sessions, from June 23 to July 2, the course will require 80 per cent attendance for students to attain completion certificates. The course is open to undergraduate, postgraduate and doctoral students from all disciplines. The other courses offered this year are 'Timeless lessons – Gita & Psychological Insights' and 'Bharat Bodha: Ancient Indian Wisdom & its Contemporary Relevance'. For more details on the course and enrolment, interested candidates can visit LSR's official website —
Time of India
29-04-2025
- Politics
- Time of India
Lady Shri Ram College Celebrates Annual Day with Tributes to Trailblazing Alumnae and Students
New Delhi: Lady Shri Ram College for Women (LSR) celebrated its annual day on Tuesday, spotlighting the exceptional accomplishments of its alumnae and students. Olympian Manu Bhaker , an LSR alumna, who was felicitated for her historic achievement at the 2024 Paris Olympics, where she became the first Indian woman shooter to win two medals in a single edition of the Games. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi The college also honoured alumna Shambhavi Choudhary , member of Parliament from Samastipur, Bihar. Recognised as a 'Promising Young Leader', Choudhary was applauded for her work in community empowerment, social justice and public advocacy. She is one of the youngest members of the 18th Lok Sabha. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How can a 3-month-old get cancer? Please help! Give Hope India Donate Now Undo Olympian Maheshwari Chauhan and current student Rhythm Sangwan were also acknowledged for their impressive performances at the 2024 Olympics. The event was inaugurated by acting principal professor Kanika Ahuja, who addressed the gathering on the theme 'Reimagining LSR' as the college marks its 70th year. She announced that LSR would soon implement the fourth year of undergraduate studies in accordance with the National Education Policy (NEP) 2020. Amitabh Kant, former CEO of NITI Aayog and India's G20 Sherpa, was the chief guest. In his address, he commended the college's commitment to holistic education that balances academic rigour with co-curricular excellence. "We are fortunate to live in a time when huge transformation is taking place and globalisation is getting questioned," Kant said. Chairperson Dr Bharat Ram attended as a special guest. He reminisced about walking hand-in-hand with his father around the then-under-construction LSR building. "He used to say, 'This is going to be the place where young girls will be educated and made the future leaders,'" Ram recalled. He also shared a heartfelt story about his grandfather, Sir Shri Ram, who conceived the idea of establishing a women's college. "At the time, he was deeply concerned by the absence of female students at SRCC. He found that many parents were hesitant to send their daughters to a co-ed college. Moved by this, he decided to create a space where women could pursue higher education freely—a vision that led to the founding of LSR," he Bharatanatyam dancer and theatre artist Geeta Chandran pledged her support to lead fundraising efforts for upgrading the college's infrastructure, especially the auditorium. In her speech, she highlighted themes of world peace, unity, and the enduring spirit of LSR, concluding her address with a musical performance. Justice Indu Malhotra, an LSR alumna from the class of 1975 and former Judge of the Supreme Court of India, was honoured with the Distinguished Alumna Award. "In the past two decades, women have entered various fields. After the 90s, doors opened for women in the professional world. The entry of women into police services has made some difference, but the count is low. There needs to be more representation. I believe if there is more representation, then the problem could be solved," she said. The celebrations also featured the release of the Annual Report 2025, the latest edition of the college magazine, and over 20 academic journals from various departments. More than 400 students were recognised for excellence in academics, leadership, environmental initiatives, and co-curricular achievements.
Associated Press
24-03-2025
- Business
- Associated Press
Arthur J. Gallagher & Co. Acquires Litchfield Special Risks, Inc.
ROLLING MEADOWS, Ill., March 24, 2025 /PRNewswire/ -- Arthur J. Gallagher & Co. today announced that its U.S. wholesale brokerage, binding authority and programs division, Risk Placement Services, Inc. (RPS), has acquired El Paso, Texas-based Litchfield Special Risks, Inc. (LSR). Terms of the transaction were not disclosed. LSR is a wholesale insurance broker and managing general agency (MGA) specializing in transportation and property/casualty solutions for retail agents in Texas and the Southwest US. Bill Brenton and his team will remain in their current location under the direction of Ash Thomas, VP-Western Region for RPS. 'LSR's market reputation and transportation niche expertise will expand RPS's capabilities in Texas,' said J. Patrick Gallagher, Jr., Chairman and CEO. 'I am excited to welcome Bill and his associates to our growing team.' Arthur J. Gallagher & Co. (NYSE:AJG), a global insurance brokerage, risk management and consulting services firm, is headquartered in Rolling Meadows, Illinois. Gallagher provides these services in approximately 130 countries around the world through its owned operations and a network of correspondent brokers and consultants.
Telegraph
01-03-2025
- Sport
- Telegraph
The quest to set a 450mph speed record could pioneer frictionless travel on water
You might wonder how it is that Richard Noble OBE, entrepreneur and holder of the land speed record (LSR) between 1983 and 1997, is now, at the age of 79, considering a tilt at inspiring the fastest person on water. Surely this consummate record-breaker should be settled back enjoying his trophies and a mug of Horlicks, rather than heading up a team aimed at another record? After all, he played such a crucial part in the Thrust SSC record of 763.035mph in 1997 and its almost-but-not-quite LSR successor, Bloodhound. The water speed record (WSR) of 317mph has stood for the past 46 years, held by Ken Warby and his Spirit of Australia hydroplane. The clue comes in Noble's autobiography, Take Risk!, in which he reveals that when he was six he saw and was inspired by three-times land speed record-holder John Cobb's Crusader WSR boat on Loch Ness in 1952. 'This started me on a quest for the land-speed record,' he writes. (The history of record-breaking on water, including Cobb's Crusader, is detailed below.) He's far from starry-eyed about the dangers of such a project, which are horrendous. Water is around 800 times more dense than air, so hitting it at any speed is extremely hazardous, often fatal. It's almost never flat, with imperceptible swells and waves that can deflect a craft, while it can also contain semi-submerged hazards or pockets of different density, which can cause instability. Seven of the 13 people who have attempted to break the WSR since 1930 have perished in the attempt; the only men who tried to beat Warby's 1978 record, Lee Taylor in 1980 and Craig Arfons in 1989, died in the process. In short, Warby is the only man to have exceeded 300mph on water and survived. With a target of 450mph, has Noble finally met his match, or is the prize of almost-friction-free travel over water too valuable not to at least have a go at it? Other WSR efforts There are currently three other record attempts, all planned with hydroplane hulls. The first is the spiritual successor to Warby's Spirit of Australia, Spirit of Australia II, which was commenced by Ken Warby with his son David, who continued the work after the death of his father, aged 83, in 2023. The craft has more than twice the power of its predecessor thanks to its Rolls-Royce Orpheus 803 jet and plenty of potential. Motor Boat and Yachting magazine reported in autumn of 2024 that Warby, having achieved 260mph in testing, had experienced a bird strike into the engine's turbine blades, which put things back. Quicksilver is a UK effort led by Nigel Macknight, which started as a partnership with Ken Norris, the designer of Bluebird K7 and doyen of speed record-breaking. It's a stepped hydroplane design with input from high-speed boat designer Lorne Campbell and aerodynamicist Mike Green, powered by a Rolls-Royce Spey jet engine. Things have been quiet on the project for a few years as Covid and personal tragedy affected the team, but it's far from dormant. 'The water speed record is really, really difficult and dangerous,' comments Macknight, 'and I've every respect for Richard Noble's effort. I don't really see these things in terms of rivals, as it's not helpful, but while we've lost momentum, we're hopeful and optimistic.' Another British project, Longbow, is under construction at Blackpool, Lancashire. Its project manager, David Aldred, was interviewed by BBC North West in January this year. He worked on the restoration of Donald Campbell's 1950s Bluebird K7 and helped source a new engine for the craft prior to its planned return to Coniston Water next year. Standing in front of his twin-engined, wood-framed hydroplane, he said: 'Unlike the land speed record, which is done in the desert and is just a YouTube video, this will be done in the Lake District, where you can come and see it, skimming across the water, with a guy putting his life on the line, to get the record for Britain.' Embracing risk Undeterred by rivals or risk, Noble is pressing on. He has little truck with what he sees as an aversion to risk in the UK Government and companies, asserting that taking on 'really big risks is the way to succeed'. ''Highly dangerous' for us is ideal, and we offset that risk with design and innovation,' he says. If it sounds crazy, the track record of the Thrust and Bloodhound teams is of brilliant and innovative design along with extensive research backed by solid data and meticulous safety, all of which resulted in the LSR for ThrustSSC and a top speed of 628mph for Bloodhound in November 2019.
Yahoo
15-02-2025
- Business
- Yahoo
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're already doing better in 2025, though. And there are good reasons to think both could maintain a strong performance throughout the year. Here's why. Vertex Pharmaceuticals performed well for much of 2024. The stock slid during the year's final months, culminating in a massive one-day drop prompted by a clinical setback. In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful lumbosacral radiculopathy (LSR), a condition that causes pain in patients' lower backs, hips, and legs. While Vertex will advance the medicine to phase 3 studies in this indication, the market isn't convinced it will be successful. However, Vertex remains an attractive stock. Since that setback, the biotech has earned approval for Alyftrek, a next-generation medicine in its core area of expertise, cystic fibrosis (CF). Furthermore, suzetrigine earned its first indication in treating moderate to severe acute pain -- where it is marketed as Journavx -- becoming the first of a new class of oral non-opioid pain inhibitors on the market. These regulatory wins (especially the second) are lifting Vertex's stock, a rally that could continue for much of the year. Alyftrek should start making some noise, as will Journavx. Vertex's Casgevy, a gene-editing treatment for two rare blood-related diseases that has been on the market for a little over a year, could also contribute to the company's financial results. Vertex should see more pipeline progress, too. The company has a duo of novel medicines in phase 3 studies and several more in earlier stages of development. So, after a subpar 2024, Vertex Pharmaceuticals could perform much better in 2025. What's more important, though, are the company's long-term prospects. And on that front, investors have little to worry about today. Vertex's strategy of developing medicines in areas with large unmet needs has proven to work. The company's dominance in CF in the past decade -- which led to excellent financial results and stock-market performances -- proves as much: Vertex's approvals in areas beyond CF and its exciting pipeline make it a great biotech stock to buy. AstraZeneca's financial results were strong for most of 2024, as was its stock performance. However, the company faced legal issues in the last few months of the year. Some of its executives in China, including its former president in the country, Leon Wang, have been the subject of investigation by the authorities there. That's on top of an insurance fraud investigation and allegations of smuggling of unapproved drugs, also in China. These issues have weighed on AstraZeneca's stock, and certainly add some degree of uncertainty to the company's prospects. However, AstraZeneca's legal problems stem from its operations in China, which strongly suggests wrongdoing by specific people affiliated with the company there. These issues will somewhat affect AstraZeneca's performance in the country, and the company will have to pay back unpaid importation taxes related to the smuggling of unapproved drugs in China. But as AstraZeneca starts moving beyond this issue, its stock price will bounce back. The drugmaker once again proved the strength of its underlying operations in the fourth quarter. The company's revenue of $14.9 billion grew by 24% year over year, a very strong performance by a pharmaceutical giant. AstraZeneca's earnings per share (EPS) soared by 44% year over year to $2.09. Its shares jumped following its earnings release. Even with the China-related issues, AstraZeneca expects its revenue in 2025 to grow by a healthy high-single-digit percentage and its EPS by low double digits. Elsewhere, it expects well over a dozen clinical trial readouts this year, including for AZD6234, a potential anti-obesity medicine. Between AstraZeneca's current lineup, which is still producing excellent results, and its deep pipeline that will lead to plenty of approvals and label expansions, the drugmaker has strong long-term prospects. If not for its issues in China, AstraZeneca's shares would almost certainly be in the green over the trailing-12-month period, so that headwind is already factored into its stock price. If it can deal with that problem, AstraZeneca could perform much better this year. And the stock could also deliver outsized returns to long-term investors. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $350,809!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $45,792!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $562,853!* Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of February 3, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Tumbled in Could See an Impressive Comeback in 2025 was originally published by The Motley Fool Sign in to access your portfolio
